Intravenous Exenatide in Patients With Acute Brain Injury

NCT02058940 on ClinicalTrials.gov · last registry update 2018-07-12

A small phase 4 — 8 participants, against a typical 75. The sponsor logged completion for August 2017. Primary outcome, as filed: Percentage of Critically Ill Patients With Acute Brain Injury Achieving Pre-specified Feasibility Criteria.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: University of North Carolina, Chapel Hill
Sponsor type: Other
Enrollment: 8
Started: 2015-08
Primary completion: 2017-08 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage of Critically Ill Patients With Acute Brain Injury Achieving Pre-specified Feasibility Criteria

Conditions studied

Brain Injuries

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.